For a patient with suspected acute coronary syndrome, which agent is not part of the recommended management?

• A. Nitroprusside
• B. Aspirin
• C. Oxygen
• D. Nitroglycerin

Answer: (A)

In suspected acute coronary syndrome, the goal is to quickly reduce myocardial injury by inhibiting platelets, improving oxygen delivery if needed, and relieving ischemia. Aspirin fits this approach as a cornerstone therapy because it irreversibly inhibits platelet aggregation, helping prevent further thrombosis and reducing mortality.

Oxygen is given when the patient is hypoxemic or in respiratory distress to ensure adequate oxygen delivery to ischemic myocardium. Nitroglycerin helps relieve chest pain and decreases myocardial oxygen demand by dilating veins (and some arteries) as long as blood pressure remains stable, which improves perfusion to the heart and can reduce ischemia.

Nitroprusside, however, is not part of routine ACS management. It is a powerful vasodilator used in hypertensive emergencies or acute decompensated heart failure. In ACS, it can cause significant hypotension, which lowers coronary perfusion pressure and can worsen myocardial ischemia. Therefore, it is not routinely recommended for suspected ACS unless there are specific indications (like severe hypertension or pulmonary edema) and is used with caution under specialist guidance.

So, the agent not part of the standard ACS management is the vasodilator nitroprusside.